Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 705

1.

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE.

Am J Epidemiol. 2009 Jul 1;170(1):12-23. doi: 10.1093/aje/kwp115. Epub 2009 May 25.

2.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators.

JAMA. 2002 Jul 17;288(3):321-33.

PMID:
12117397
3.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB.

JAMA. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040.

4.

[Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study].

Heinemann V, Parhofer K.

Internist (Berl). 2003 Jul;44(7):896-8. German. No abstract available.

PMID:
14631586
5.

Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.

Banks E, Canfell K.

Am J Epidemiol. 2009 Jul 1;170(1):24-8. doi: 10.1093/aje/kwp113. Epub 2009 May 25.

PMID:
19468078
6.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee.

JAMA. 2004 Apr 14;291(14):1701-12.

PMID:
15082697
7.

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators.

JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.

8.

The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.

Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F.

J Steroid Biochem Mol Biol. 2014 Jul;142:4-11. doi: 10.1016/j.jsbmb.2013.10.009. Epub 2013 Oct 27. Review.

PMID:
24172877
9.

Women's health. The vanishing promises of hormone replacement.

Enserink M.

Science. 2002 Jul 19;297(5580):325-6. No abstract available.

PMID:
12130763
10.

Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke.

Prentice RL.

Semin Reprod Med. 2014 Nov;32(6):419-25. doi: 10.1055/s-0034-1384624. Epub 2014 Oct 16. Review.

11.

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; HERS Research Group.

JAMA. 2002 Jul 3;288(1):58-66.

PMID:
12090863
12.

Estrogen with and without progestin: benefits and risks of short-term use.

LaCroix AZ.

Am J Med. 2005 Dec 19;118 Suppl 12B:79-87.

PMID:
16414331
13.
14.

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ.

Ann Intern Med. 2000 Dec 19;133(12):933-41.

PMID:
11119394
15.

Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.

Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA.

Ann Intern Med. 2010 Feb 16;152(4):211-7. doi: 10.7326/0003-4819-152-4-201002160-00005.

16.
17.

Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.

Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators.

Am J Epidemiol. 2006 Apr 1;163(7):589-99. Epub 2006 Feb 16.

PMID:
16484450
18.

Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.

Col NF, Pauker SG, Goldberg RJ, Eckman MH, Orr RK, Ross EM, Wong JB.

Arch Intern Med. 1999 Jul 12;159(13):1458-66.

PMID:
10399897
19.

Is the WHI relevant to HRT started in the perimenopause?

Harman SM, Brinton EA, Clarkson T, Heward CB, Hecht HS, Karas RH, Judelson DR, Naftolin F.

Endocrine. 2004 Aug;24(3):195-202.

PMID:
15542885
20.

Hormone replacement therapy and cancer.

[No authors listed]

Gynecol Endocrinol. 2001 Dec;15(6):453-65. Review.

PMID:
11826770

Supplemental Content

Support Center